Email Updates

Search form

You are here

Webinar: Advocates’ Debrief on the Science of Daily F/TAF vs. TDF/FTC as PrEP

October 7, 2019

on Monday, October 7 at 9-10am ET, AVAC, the Treatment Action Group (TAG), The Well Project and the Women’s Research Initiative (WRI) co-convened the webinar Advocates’ Debrief on the Science of Daily F/TAF vs. TDF/FTC as PrEP.

This webinar was the first in a two-part series, responding to advocates’ desire to better understand the research to date on F/TAF as PrEP, especially as it relates to its safety profile [compared to TDF/FTC] and the lack of robust data in cisgender women. This issue came into greater focus during an August 7 FDA advisory committee meeting at which Gilead’s regulatory submission of F/TAF for PrEP was discussed and debated.

On the webinar, AVAC, TAG, The Well Project and WRI representatives were joined by researchers Andrew Hill (Senior Visiting Research Fellow in the Pharmacology Department at Liverpool University) and Monica Gandhi (Professor of Medicine and Associate Division Chief of the Division of HIV, Infectious Diseases, and Global Medicine at UCSF/San Francisco General Hospital). They shared their take on the latest research, contextualized the August 7 discussion, and helped to inform an advocacy agenda for next steps.

For background, check out AVAC’s blog for a recap of the advisory committee proceedings, as well as TAG and PrEP4All’s joint comment to the FDA.

Recording and Slides: YouTube / Andrew Hill's slides / Monica Gandhi's slides